Regeneron's garetosmab nears FDA verdict on 94% HO-lesion cut in FOP
The FDA is due to rule on garetosmab by the end of August 2026, weighing a Priority Review BLA built on OPTIMA's Phase 3 lesion-reduction data against a trial whose primary endpoint was safety, not lesion count.
Executive Summary
- The FDA is weeks from ruling on a Phase 3 Priority Review application for the first drug designed to stop new bone growth in a disabling, ultra-rare genetic disease, with no approved treatment currently available.
- Regeneron's disclosed results show large reductions in new bone lesions at both doses tested against placebo, though the trial was designed and registered primarily to test safety rather than this efficacy comparison.
- Garetosmab has no other clinical-stage neutralizing antibody targeting the same lesion-driving mechanism in this disease, and the closest rival programs use unrelated small-molecule mechanisms still in earlier-phase testing.
- Regeneron's earlier attempt to bring the same drug to Japanese FOP patients was withdrawn before enrollment, a fact worth weighing alongside the sponsor's broader trial completion history.
The catalyst
The FDA accepted Regeneron's Biologics License Application for garetosmab under Priority Review on February 19, 2026, setting a target action date in August 2026 for adults with fibrodysplasia ossificans progressiva (FOP). Garetosmab is a monoclonal antibody that blocks Activin A, a protein Regeneron identifies as central to the abnormal bone formation that defines the disease. The FDA had earlier granted the drug both Fast Track and Orphan Drug designations for preventing heterotopic ossification in FOP, and it also holds Orphan Designation in the European Union. If cleared, Regeneron said garetosmab would be the first available treatment shown to reduce the number and volume of new bone lesions in adults with the disease. GaretosmabGaretosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of ...Feb 19, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial showed
The BLA rests on the Phase 3 OPTIMA trial (NCT05394116), a 63-patient, placebo-controlled study testing garetosmab at 3 mg/kg and 10 mg/kg doses. At Week 56, patients on the 3 mg/kg dose developed a single new heterotopic bone lesion versus 19 on placebo, a 94% reduction (p=0.0274), while those on 10 mg/kg developed two new lesions versus the same 19, a 90% reduction (p=0.0260). A post-hoc analysis found lesion volume fell more than 99% at both doses compared with placebo. Serious treatment-emergent adverse events occurred in five of 63 patients across both dose arms and placebo combined, and the most common adverse reactions, occurring in 30% or more of patients, were nosebleeds, increased hair growth, abscess, and acne. NCT05394116+1A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)NCT05394116Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of ...Feb 19, 2026
The endpoint question
OPTIMA's registered primary endpoint is the incidence and severity of treatment-emergent adverse events of special interest, a safety measure, not the lesion-count comparison the BLA highlights. The lesion reductions Regeneron reported carry p-values below 0.05, and the volume reductions carry "nominal" p-values, a labeling the company itself attached to the post-hoc analysis. The trial's primary completion date shifted six times between 2022 and 2025, moving from March 2025 to a final date of July 17, 2025, and enrollment was trimmed from an anticipated 66 to 63 patients when the trial closed to new participants in mid-2024. The enrollment change sits within the routine range the operational model tracks for a study of this size, and eligibility criteria were amended five times over the trial's life. NCT05394116+1A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)NCT05394116Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of ...Feb 19, 2026
The competitive frame
No other Activin A-neutralizing antibody is in clinical testing for FOP; the field's active trials instead use small-molecule mechanisms against different targets, including Ipsen's palovarotene (a RAR-gamma agonist) and Incyte's zilurgisertib and Ipsen's fidrisertib (both ACVR1-pathway inhibitors), each still in Phase 2 or Phase 3 testing for the same disease. Regeneron's own earlier Phase 3 attempt to study garetosmab in Japanese FOP patients was withdrawn in March 2022 before it enrolled, and a companion Phase 3 study in children and adolescents (NCT07559513) has not yet begun recruiting. Outside FOP, Activin A-pathway drugs including Merck's sotatercept and Bristol-Myers Squibb's luspatercept are already approved and marketed for pulmonary arterial hypertension and myelodysplastic syndromes respectively, unrelated indications that establish the target's clinical validity elsewhere but do not extend to this disease. With no approved disease-modifying option in FOP today, the bar this decision sets is whether garetosmab's lesion-reduction signal, generated as a secondary comparison in a safety-primary trial, holds up as the basis for a label the FDA is willing to grant without restriction.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.